Analysts have been eager to weigh in on the Healthcare sector with new ratings on HUTCHMED (HCM – Research Report), Bayer (BAYRY – Research Report) and Compass Therapeutics (CMPX – Research Report).
HUTCHMED (HCM)
In a report released today, Paul Choi from Goldman Sachs maintained a Hold rating on HUTCHMED, with a price target of $17.00. The company’s shares closed last Wednesday at $19.50, close to its 52-week high of $21.28.
According to TipRanks.com, Choi is a 4-star analyst with an average return of
Currently, the analyst consensus on HUTCHMED is a Moderate Buy with an average price target of $23.00.
See Insiders’ Hot Stocks on TipRanks >>
Bayer (BAYRY)
In a report released today, Joel Jackson from BMO Capital maintained a Hold rating on Bayer, with a price target of EUR55.00. The company’s shares closed last Wednesday at $11.07, close to its 52-week low of $10.53.
According to TipRanks.com, Jackson is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Bayer with a $54.64 average price target.
Compass Therapeutics (CMPX)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Compass Therapeutics, with a price target of $10.00. The company’s shares closed last Wednesday at $1.72, close to its 52-week low of $1.64.
According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of
Compass Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $10.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HCM:
- HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
- HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023
- Hutchmed announces Takeda submits fruquintinib NDA to Japan MHLW
- HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
- HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
